The upcoming therapies, Epidiolex by GW Pharmaceuticals and JBPOS0101 by BioPharm Solutions, are anticipated to generate a decent West Syndrome market revenue in the forecast period of 2021-2030.
LAS VEGAS, July 14, 2021 /PRNewswire/ -- DelveInsight's "West Syndrome Market" report provides a thorough comprehension of the West Syndrome historical and forecasted epidemiology and the West Syndrome market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The West Syndrome market report also proffers an analysis of the current West Syndrome treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Epidiolex has been granted Orphan Drug Designation for the treatment of West Syndrome patients by the US FDA.
The Cannabidiol therapies by BioPharm Solutions and GW Pharma, once approved, will drive the West Syndrome market revenue.
West Syndrome Market will boom due to companies' clinical development activities, product innovations, and technological advancements. There is support from various organizations to increase awareness of the disease. Also, a growing number of births and rising West Syndrome prevalence is observed.
The factors such as delayed diagnosis and treatment, serious side effects of medications, lack of prevalence-based studies, challenges in conducting clinical trials, and lack of late phase clinical studies will hamper the West Syndrome Market growth.
Several key pharmaceutical companies include Lundbeck, Questcor Pharmaceuticals, Mallinckrodt Pharmaceuticals, GW Pharmaceuticals, BioPharm Solutions, and others, are developing novel products to improve the West Syndrome treatment outlook.
Apart from these, various other companies such as Catalyst Pharmaceuticals and Avanex Life Sciences Corporation are exploring their therapeutics for infantile spasms in the early stages of clinical development.
Looking at the historical trend of emerging therapies, their probability of success in entering the West Syndrome market remains a bit low, considering that key Epilepsy players such as Marinus Pharma and Insys therapeutics did not continue developing their respective drugs owing to unsatisfactory responses. Later, Insys therapeutics winded down its operations.
West Syndrome is an age-related specific epileptic encephalopathy due to multiple and diverse causes. It is characterized by a unique type of seizure called epileptic (infantile) spasms and gross EEG abnormalities of hypsarrhythmia.
The current treatment of West Syndrome involves Hormonal Therapy (ACTH), Vigabatrin, Corticosteroids, and other off-label therapies, among the most common medications used as a first-line treatment option. On the other hand, Anti-epileptic Drugs (AEDs) form the second-line treatment for West Syndrome patients. ACTH (Adrenocorticotropic hormone) is probably the most universally accepted first-line treatment and the most effective in treating West Syndrome.
Along with ACTH, corticosteroids are also usually the first line of treatment options for the disease. Prednisolone is appealing because of its low cost, ready accessibility in many countries, ease of administration, and increasing evidence that it may be similar in efficacy to ACTH and vigabatrin.
There are two approved products, namely Sabril (vigabatrin) and Acthar Gel (corticotropin injection), to treat the West Syndrome. Out of these two therapies, vigabatrin is approved in the US, Europe, and Japan; however, Acthar Gel is only approved in the US and is used as off-label therapy in the other two regions. In addition, in Europe, vigabatrin is marketed by Orphelia Pharma by the brand name Kigabeq.
The current West Syndrome emerging market lacks a robust pipeline with GW Pharma and BioPharm Solutions as major players, Epidiolex (GW Pharmaceuticals) is in its phase III developmental stage, whereas BioPharm Solutions is conducting a phase II clinical developmental trial for its antiepileptic drug candidate JBPOS0101, but the results of this trial have not been published yet.
To conclude, the West Syndrome Market growth will enlarge since many companies are innovating. The technological advancements will help in better diagnosis and treatment, thereby resulting in a lucrative market opportunity. The current treatment options are very few for treating patients with West syndrome, which opens a platform of new therapies to enter the market. The key West Syndrome pipeline therapies are expected to get launched in the market as early as possible, hold several partnerships and collaborations, and designations from the FDA.
Nevertheless, the growth of the West Syndrome Market might be hindered due to the lack of awareness of indication among healthcare providers, which results in delays in diagnosis and treatment. There are only two approved therapies to date to treat West syndrome (vigabatrin and corticotropin injection), which also have adverse side effects. In addition, various issues are faced while conducting West Syndrome clinical trials, impacting the actual analysis. There is a lack of late-phase clinical studies, which means not many therapies will be approved anytime soon.
DelveInsight's EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. Key players are AstraZeneca, Pfizer, Novartis Pharmaceuticals, Janssen Research & Development, Yuhan Corporation, Takeda, and others.
DelveInsight's Adult Myopia Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Key players are Genentech, Bayer AG, and others.
DelveInsight's Malignant Pleural Mesothelioma (MPM) - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and in historical and forecasted West Syndrome epidemiology in 7MM.
DelveInsight's Meniscus Tear Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Metastatic Bone Cancer Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also providesBusiness Consulting Serviceswith a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.